摘要
随着医学治疗新技术的发展,由基因测序、分子诊断、靶向药物等发展而来的精准医疗为多种难治性疾病带来治愈的希望。CD_(38)的靶向治疗药物单克隆抗CD_(38)抗体达雷妥尤已被国内外应用于治疗复发难治性多发性骨髓瘤,但达雷妥尤会对抗人球蛋白血型血清学试验造成干扰,给输血试验室带来重大挑战。本文综述国内外达雷妥尤治疗对输血的影响及采取的各种解决方法,输血试验室在遇到此类患者时可根据各自的情况在输血相容性试验前进行处理。
With the development of new medical treatment technology,precision therapy developed by gene sequencing,molecular diagnosis,targeted drugs,etc.,has brought hope for the cure of a variety of refractory diseases.The monoclonal anti-CD_(38) antibody daratumuyu,a targeted therapy drug of CD_(38),has been applied to the treatment of relapsed and refractory multiple myeloma at home and abroad.At the same time,daratumuyu treatment interferes with antihuman globulin blood group serological tests,which poses a major challenge to transfusion laboratories.This article reviews the influence of daratumuyu treatment on blood transfusion at home and abroad and the various solutions adopted.The blood transfusion laboratory can deal with such patients according to their own conditions before transfusion compatibility test.
作者
梁援
LIANG Yuan(Wuxuan County People's Hospital,Laibin 545900,China)
出处
《中国医药指南》
2023年第11期65-68,72,共5页
Guide of China Medicine
